Blog
RSS FeedPosted by Michael Wonder on 23 May 2025
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
23 May 2025 - New treatment sparsentan has been found to slow down the progression of kidney damage, which will change ...
Posted by Michael Wonder on 22 May 2025
Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
22 May 2025 - Dostarlimab, when used in combination with platinum-based chemotherapy, can be used as an option for the ...
Posted by Michael Wonder on 15 May 2025
Deal agreed for continued access to life-changing treatment for rare inherited disease
14 May 2025 - NICE is consulting on draft guidance for cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2, ...
Posted by Michael Wonder on 09 May 2025
Osimertinib mesylate in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy for patients with advanced EGFR mutation positive non-small-cell lung cancer (final guidance)
8 May 2025 - Osimertinib mesylate, when used in combination with pemetrexed disodium heptahydrate and platinum-based chemotherapy, is recommended as an ...
Posted by Michael Wonder on 08 May 2025
Brentuximab vedotin in combination with chemotherapy for the treatment of patients with stage 3 or 4 CD30 positive Hodgkin lymphoma
7 May 2025 - Brentuximab vedotin, when used in combination with doxorubicin hydrochloride, dacarbazine and vinblastine sulphate is recommended as an ...
Posted by Michael Wonder on 07 May 2025
Omaveloxolone for the treatment of patients with Friedreich’s ataxia
6 May 2025 - NICE is unable to make a recommendation on the use of omaveloxolone (Skyclarys) for the treatment of ...
Posted by Michael Wonder on 01 May 2025
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
1 May 2025 - Our final draft guidance recommends linzagolix (Yselty, Theramex) with hormonal add-back therapy for adults of reproductive age ...
Posted by Michael Wonder on 14 Apr 2025
Thousands of people a year could benefit from new twice a day tablet for advanced breast cancer
11 April 2025 - We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately ...
Posted by Michael Wonder on 10 Apr 2025
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
10 April 2025 - Today, for the first time, we have given the green light to a targeted treatment for the ...
Posted by Michael Wonder on 02 Apr 2025
Efanesoctocog alfa for the treatment and prevention of bleeding episodes in patients with haemophilia A (final guidance)
2 April 2025 - NICE has published final evidence-based recommendations on the use of efanesoctocog alfa (Altuvoct) for the treatment ...
Posted by Michael Wonder on 13 Mar 2025
First licensed treatment for ultra-rare immune disorder recommended
13 March 2025 - Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome licensed for use in the ...
Posted by Michael Wonder on 13 Mar 2025
First daily pill for endometriosis approved for NHS use
13 March 2025 - Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful ...
Posted by Michael Wonder on 12 Mar 2025
Atezolizumab for the first-line treatment of adults with advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable
12 March 2025 - NICE is unable to make a recommendation on the use of atezolizumab (Tecentriq) in the NHS for ...
Posted by Michael Wonder on 12 Mar 2025
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with claudin-18.2 positive, HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 March 2025 - NICE has published final evidence-based recommendations on the use of zolbetuximab (Vyloy) in combination with chemotherapy ...
Posted by Michael Wonder on 26 Feb 2025
Exagamglogene autotemcel for the treatment of patients with severe sickle cell disease
26 February 2025 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...